AbbVie Net Change in Short-term Investments 2012-2026 | ABBV

AbbVie annual/quarterly net change in short-term investments history and growth rate from 2012 to 2026. Net change in short-term investments can be defined as the net cash flows from the sale and purchase of investments defined to be short-term, generally with maturities of less than one year from the purchase date.
  • AbbVie net change in short-term investments for the quarter ending March 31, 2026 was $0M, a 0% increase year-over-year.
  • AbbVie net change in short-term investments for the twelve months ending March 31, 2026 was $0M, a 0% increase year-over-year.
  • AbbVie annual net change in short-term investments for 2024 was $0B, a 0% decline from 2023.
  • AbbVie annual net change in short-term investments for 2023 was $0B, a 0% decline from 2022.
  • AbbVie annual net change in short-term investments for 2022 was $0B, a 0% decline from 2021.
Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
AbbVie Annual Net Change in Short-term Investments
(Millions of US $)
2024 N/A
2023 N/A
2022 N/A
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A
2014 N/A
2013 N/A
2012 N/A
2011 N/A
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $367.673B $61.160B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $887.629B 38.81
Johnson & Johnson (JNJ) United States $574.358B 22.08
Roche Holding AG (RHHBY) Switzerland $318.782B 0.00
Merck (MRK) United States $299.893B 13.54
Novartis AG (NVS) Switzerland $293.951B 17.16
Novo Nordisk (NVO) Denmark $167.527B 9.60
Pfizer (PFE) United States $153.074B 8.33
Sanofi (SNY) France $114.048B 10.56
Bayer (BAYRY) Germany $46.178B 8.70
Innoviva (INVA) United States $1.760B 5.88